Introduction
Purines are essential building blocks for RNA and DNA synthesis, and regulate energy metabolism and transfer, and protein synthesis, function, and enzyme activity. Purines are also vital components of many essential coenzymes (NAD, NADH, FAD, Coenzyme A), and signaling molecules (cAMP, guanine nucleotides). The enzymatic steps of de novo purine biosynthesis convert PRPP (5-phospho-α-D-ribosyl-1-pyrophosphate) to IMP (inosine monophosphate), and an additional four steps convert IMP to AMP (adenosine monophosphate) or GMP (guanosine monophosphate) (Fig. 1) . Recent evidence demonstrates that the proteins carrying out de novo purine biosynthesis form a multienzyme complex, the purinosome, which is induced by acute requirement for purines [1] [2] [3] . Formation of the purinosome can be disrupted by mutations in ADSL (E.C. 4.3.2.2) and ATIC (E.C. 2.1.2.3/E.C.3.5.4.10), with severe developmental consequences in humans [3] . In addition to ADSL and ATIC, 30 enzyme defects of purine and pyrimidine metabolism have been identified and 17 of these are known to cause human disease [4] . The clinical presentation of genetic disorders of purine metabolism includes a wide variety of symptoms, such as severe combined immunodeficiency, severe neurological defects, developmental delay, and abnormal brain development [4] [5] [6] . The consequences of inborn errors in purine metabolism are poorly understood, and misdiagnosis most likely results in underestimation of their incidence and prevalence [4] .
One approach utilized in the analysis of de novo purine biosynthesis and the role of the purinosome is the use of mammalian cells with mutations in the genes encoding enzymes of the pathway. These can be cells isolated from individuals with inborn errors of purine metabolism as reported previously [3, 7] , or experimentally derived cells which carry mutations in de novo purine biosynthesis genes. We have previously reported the isolation and initial characterization of Chinese hamster Molecular Genetics and Metabolism 108 (2013) [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] ovary cell (CHO-K1) mutants presumably defective in each of the seven proteins required for de novo AMP synthesis [8, 9] . Here we report the further characterization of two of these, AdeD and AdeI. AdeD is deficient in bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS, E.C. 6.3.2.6/E.C. 4.1.1.21) activity, responsible for the conversion of AIR (5-aminoimidazole ribotide) to CAIR (5-amino-4-carboxyimidazole ribotide) and the conversion of CAIR to SAICAR (5-amino-4-imidazole-N-succinocarboxamide ribotide). AdeI is deficient in bifunctional adenylosuccinate lyase (ADSL) activity, responsible for the conversion of SAICAR to AICAR (5-amino-4-imidazolecarboxamide ribotide) and the conversion of SAMP (adenylosuccinate) to AMP (adenosine monophosphate). We previously characterized AdeI, and presented evidence that AdeI is a useful model for the cellular consequences of ADSL deficiency [10] .
The metabolic intermediates SAICAR (the product of PAICS and a substrate for ADSL) and AICAR (the product of ADSL) regulate the expression of purine pathway genes in yeast cells [11] . When purine levels are deficient, accumulated AICAR enhances binding of pho2p, pho4p, and bas1p transcription factors to purine and phosphate pathway gene promoters [11] . SAICAR enhances pho2p and bas1p binding, which specifically positively regulates purine regulon genes [11] . Whether these intermediates have similar effects in mammalian cells is not known. AICAr (the riboside form of AICAR) is a potential antitumor agent and promotes apoptosis in aneuploid cells [12, 13] . Administration of AICAr to sedentary mice mimicked the effects of exercise, resulting in increased oxidative biomarkers in cultured skeletal muscle cells and enhanced running endurance [14] . It has also been demonstrated that inhibition of adenylosuccinate lyase activity by AICAr results in skeletal muscle dysfunction, possibly through AICAR accumulation [15] .
In addition to its role in supplying the substrate for ADSL, PAICS is of interest because mutations in PAICS cause errors in vertebrate embryonic development [16] , and because PAICS shows an elevated expression in numerous cancers, and may be an important target for anticancer therapies [17, 18] . PAICS overexpression is likely due to the increased proliferation of tumor cells and consequent increased demand for purine nucleotides. Since the two steps catalyzed by PAICS in vertebrates are catalyzed by three enzymes (PurK, PurE, and PurC) in bacteria, and the mechanism of catalysis is different, PAICS is a target for antimicrobial drug development [19] . If the PAICS deficiency observed in AdeD is due to mutation in the PAICS gene, it could serve as a mammalian cell culture model for analysis of the mechanism of mammalian PAICS catalysis, which should be informative in the development of antimicrobials or vaccines that target SAICAR synthesis [20] , and the role of PAICS mutations in abnormal development, and cancer metabolism.
Disruption of de novo purine biosynthesis can result in the accumulation of intermediary metabolites in cells and body fluids. The detection of these intermediates is difficult, which is problematic for studying de novo purine biosynthesis and identifying inborn errors of purine metabolism. This may be why mutations in PAICS have not yet been found in humans. A previous study used high performance liquid chromatography (HPLC) coupled with pulsed amperometry detection to detect phosphoribosylglycinamide (GAR), the product of the second step of de novo purine biosynthesis. This suggests that electrochemical detection may be feasible for the detection of de novo purine biosynthesis pathway intermediates [21] . Since the system described requires gradient elution and has limited dynamic range, we used HPLC coupled coulometric detection (HPLC-EC) to analyze intermediate accumulation in AdeD and AdeI cells. Coulometric detection has a number of advantages over amperometric detection, including increased sensitivity, dynamic range, and simplicity of quantitation [22, 23] .
Here we report the identification of the mutations in AdeD cells in the PAICS gene and their effect on PAICS mRNA and protein expression. Moreover, we report the comparative analysis of AdeD and AdeI 
Materials and methods

Identification and analysis of PAICS mutations
2.1.1. Identification of PAICS mutations in AdeD by RT-PCR Total RNA was isolated from CHO-K1 and AdeD cells using the RNAqueous4PCR kit (Ambion). AdeD and CHO-K1 cDNA was prepared from the isolated total RNA using the RETROscript kit (Ambion). The PAICS cDNA was amplified with appropriate PCR primers (Table 1) using the Expand Hi-Fidelity PCR kit (Roche) and thermocycler parameters: 95°C for 5 min, (95°C for 30 s, 60°C for 30 s, and 72°C for 30 s) for 35 cycles, and 72°C for 7 min. PCR products were analyzed by TAE agarose gel electrophoresis. Single bands were excised from the gel and the PCR product was purified using the Zymoclean Gel DNA Recovery kit (Zymo Research). DNA concentration was estimated using TAE agarose gel electrophoresis by comparison with Low Mass DNA or High Mass DNA ladders (Invitrogen). DNA samples containing~60 ng/kb fragment length were sequenced by the University of Colorado Cancer Center DNA Sequencing and Analysis Core.
Sequence alignment with BLAST [24, 25] using the Mus musculus PAICS cDNA sequence (NCBI NM_025939.2) identified a CHO PAICS cDNA sequence, JP049561.1. Primers for RT-PCR were designed using the JP049561.1 sequence, however, nucleotides + 1 to + 217 were missing from the 5′-end. A reference CHO PAICS cDNA sequence was constructed by adding 431 nt from a predicted sequence for CHO PAICS (NCBI XM_003513528.1, 2168 bp) onto the 5′-end of JP049561.1. All PAICS RT-PCR primers (Table 1) were numbered relative to the + 1 nucleotide in the XM_003513528.1 sequence. The PAICS amino acid sequence derived from JP049561.1 is identical to that from XM_003513528.1, except JP049561.1, like human, mouse, and rat PAICS sequence, has a K at p.418, while XM_003513528.1 has a Q at this position. The resulting CHO reference sequence was used to perform alignments with sequencing data from CHO-K1 and AdeD cDNA. The Needle program at the European Bioinformatics Institute (http://www.ebi.ac.uk) was used for pairwise alignments with our CHO reference sequence. After identification of polymorphisms in the CHO-K1 and AdeD RT-PCR data, sequencing reads were translated in all reading frames to determine whether any SNP resulted in an amino acid change.
Cloning of PAICS from CHO-K1 and AdeD cDNA
PAICS was amplified from CHO-K1 and AdeD cDNA using the same PCR protocol described above for RT-PCR. However, the Expand HiFidelity Long Template PCR kit (Roche) was used instead of the Expand Hi-Fidelity Template PCR kit (Roche), following the manufacturer's protocol. The In Fusion PCR primers for PAICS are 5U-IF-PAICS-4F and 3U-IF-PAICS-4R ( Table 1 ). The PCR reactions were cleaned using the Nucleospin Plasmid kit (Clontech).
The pTarget vector (Promega) was linearized overnight with Sma I restriction endonuclease and cleaned. The DNA concentration of linearized pTarget and PAICS AdeD PCR product was determined by gel electrophoresis as described earlier. The In Fusion HD Cloning kit (Clontech) was used to ligate the PAICS AdeD In Fusion RT-PCR products into the pTarget vector.
Mini-preps and DNA sequencing of PAICS-AdeD and PAICS-CHO-K1-pTarget clones
Mini-preps of plasmid DNA from ampicillin-resistant clones were performed using the Nucleospin Plasmid kit (Clontech). TAE agarose gel electrophoresis was used to estimate the size of plasmids recovered from PAICS-AdeD-pTarget and PAICS-K1-pTarget clones, and to estimate DNA concentration. DNA sequencing was performed using the T7, pTarget seq, 807F, 1095R, and 1265R CHO PAICS primers (Table 1) . Samples were sequenced by the University of Colorado Cancer Center DNA Sequencing and Analysis Core.
Maxi-prep of PAICS-K1-pTarget, E177K-PAICS-pTarget, and
W363Stop-PAICS-pTarget plasmids DNA maxi preps were performed using the Nucleobond Xtra Midi Plasmid DNA Purification kit (Clontech) according to the manufacturer's protocol, with some modifications. The kit comes with a filter to clarify cell lysates simultaneous with column purification. We clarified cell lysates by centrifugation at 12,000 × g (8500 RPM) for 50 min in a Sorvall RC-5B Superspeed Centrifuge, followed by filtration. The plasmid DNA was concentrated and desalinated by using the NucleoBond Finalizer Plasmid DNA Concentration and Desalination kit (Clontech). The quality and quantity of plasmid DNA was quantified by UV spectroscopy at 260 and 280 nm.
2.1.5. Transfection of cDNA expression plasmids PAICS-K1-pTarget, E177K-PAICS-pTarget, and W363Stop-PAICS-pTarget into AdeD
For each plate, 500 μl OptiMEM I reduced serum medium (Gibco), 20 μl Lipofectamine 2000 (Invitrogen), and 8 μg total DNA were combined according the manufacturer's protocol (Invitrogen Lipofectamine 2000). The transfection mixture was added to confluent 60 mm plates of AdeD cells and incubated overnight at 37°C, 5% CO 2 . After 24 h, the medium was replaced with F12 medium supplemented with 10% FCS, Normocin (100 μg/ml), and 3 × 10 −5 M adenine. After an additional 24 h, the medium was changed to F12 medium containing Geneticin (400 μg/ml) for selection of pTargettransfected cells and supplemented with 10% FCS, Normocin (100 μg/ml), and 3 × 10 
Western blot analysis for PAICS protein
Total CHO-K1, AdeD, and AdeI protein (20 μg/lane) was separated by SDS-PAGE (10% gel) for 4 h at 130 V. The gel was wet-blotted to PVDF membrane in blotting buffer (48 mM Tris, 39 mM glycine, 1.3 mM SDS, 20% methanol) at 100 mA constant current for 2 h. The blot was blocked overnight at 4°C in block solution (5% BSA, 1 × PBS, 0.05% Tween-20, pH 7.4) followed by a 3 hour incubation in anti-PAICS antibody (Sigma-Aldrich HPA035895) diluted 1:150 in block solution. This was followed by five washes (1, 3, 5, 10 and 15 min) in wash solution (1× PBS/0.05% Tween-20). The blot was then incubated in goat anti-rabbit IgG-HRP conjugate (Pierce-Thermo Scientific 31460) diluted 1:10,000 in block solution for 40 min followed by five washes in wash solution. Blots were treated with chemiluminescent SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) and visualized on a Syngene Genomic and Proteomic Gel Documentation System (Syngene, Cambridge, UK). The blot was rinsed in 1× PBS and incubated in mouse monoclonal anti-GAPDH antibody (Sigma-Aldrich G8795) diluted 1:10,000 in block solution for 90 min, followed by five washes. The blot was then incubated in goat anti-mouse IgM-HRP conjugate (Pierce-Thermo Scientific 31440) diluted at 1:20,000 in block solution for 40 min, followed by five washes and visualized as described above.
Expression levels of PAICS transcript in CHO cells
PAICS expression levels in CHO cells (AdeD and CHO-K1) were determined by quantitative PCR (qPCR) and ΔΔCt analyses. Total RNA isolation and subsequent cDNA synthesis were carried out as described above (Materials and methods Section 2.1). The cDNA was used as a template in 25 μl reactions using the iQ SYBER Green Supermix kit (BioRad) with 500 nM CHO specific PAICS primers ( Table 1) . The qPCR cycling conditions were as follows: 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 30 s followed by SYBER Green data collection, and extension at 72°C for 30 s. CHO beta-actin was amplified as a reference control using specific primers (Table 1) .
HPLC-EC analysis of CHO mutant intermediate accumulations
Accumulation of intermediates
CHO-K1 and the various adenine-requiring mutants were grown in 60 mm dishes in αMEM supplemented with 10% fetal calf serum (FCS), 3 × 10 −5 M adenine, and 100 μg/ml Normocin. Accumulation of intermediates was induced by growth in purine-free medium (purine starvation) as follows. The medium in confluent plates was replaced with either fresh αMEM containing 10% FCM (twice dialyzed FCS), Normocin, and 10 −4 M adenine (which we have previously shown drastically reduces de novo purine biosynthesis in CHO cells [8] ) or with fresh αMEM containing FCM and Normocin but lacking adenine. The cells were then incubated for 4-6 h. After incubation plates were washed twice with 1 ml cold 1 × PBS then incubated for 30 min in 500 μl of 80% ethanol at 4°C. The plates were scraped with a cell scraper and the ethanol/extract mixture was transferred to a 1.5 ml microcentrifuge tube and centrifuged for 10 min at 14,000 × g at 4°C.
The supernatant was transferred to a microcentrifuge tube and immediately frozen at −80°C. The frozen extracts were dried under a vacuum in a SpeedVac. The concentrated samples were resuspended in 200 μl HPLC grade water [ultrapure (18.2 MΩ cm) water, which was filtered through 0.2 μm filter and polished through a C18 Sep-Pak column]. Resuspended samples were centrifuged for 15 min at 14,000 × g at 4°C to remove any remaining cellular debris prior to analysis.
HPLC-EC analysis
Separation and measurement of CHO mutant intermediate accumulation were performed using reverse phase HPLC-EC with a TSKgel ODS-80Tm C-18 column (250 mm × 4.6 mm ID, 5 μm) protected by a Tosoh Bioscience TSKgel guard cartridge. A column temperature of 35°C was maintained throughout the analysis. A mobile phase consisting of 50 mM lithium acetate, 2% acetonitrile, 5 mM tetrabutyl ammonium phosphate (TBAP), pH 4.8 was delivered isocratically at a flow rate of 0.7 ml/min. Sample extracts and standards were kept at 10°C until a 20 μl aliquot of each sample was injected by using an ESA autosampler (model 542). After injection and separation, analytes were detected using a CoulArray HPLC system (model 5600A, ESA) with three electrochemical detector modules. Each module contains four flow-through coulometric detectors in series set to a range of potentials from 0 to 900 mV in 100 mV increments. Also in series with the coulometric detectors was a UV detector set at 242 nm. ESA CoulArray software was used for baseline correction and analysis of all samples.
HPLC-EC standards
Standards used in the HPLC-EC analysis were diluted in HPLC grade water (see above) prior to injection. SAICAR and AIR standards are not commercially available. SAICAR was synthesized and validated using our previously published methods [26, 27] . AIR was synthesized using protocols to be published at a later date, and validated by mass spectrometry.
Results
Identification of the PAICS mutations in AdeD cells
We have shown previously that AdeD cells apparently accumulate AIR, due presumably to mutation of the PAICS gene [9] . The cDNA coding region for CHO-K1 and mouse PAICS is 1278 nucleotides long with 426 codons including the TAA stop codon. Sequencing of PAICS RT-PCR products from CHO-K1 and AdeD cells provided approximately 80% of the PAICS cDNA sequence. Comparison to our reference PAICS cDNA sequence revealed two sequence variants unique to AdeD, and one sequence variant common to both AdeD and CHO-K1 (Table 2) . This latter variant is p.I237V (c.A709G), located in the loop between β14 and α5. A BLAST search reveals that most organisms (including mouse and human) have a V at this position, and we tentatively hypothesize that V is the correct residue in CHO cells. Interestingly, p.237 is missing in the structure of human PAICS (2H31.pdb); "Asp221- Thr238 were not visible in the electron density map and assumed being disordered in the crystal" [28] . This suggests that the region containing p.237 is quite flexible, and that replacement of valine with isoleucine (a conservative change) would have little effect on the monomer structure.
The two variants found only in AdeD PAICS are p.E177K (c.G529A), located in α4, and p.W363* (c. G1088A), located in α9. The AdeD and CHO-K1 cDNAs were ligated into pTarget and sequenced. The sequences were compared to the PAICS reference sequence described earlier (431 nt from a predicted CHO-K1-PAICS sequence stitched to the 5′-end of JP049561.1). Our CHO-K1 PAICS sequence is presented (see Fig. 2 ) and differs from our reference sequence at c.G-5A (upstream of the coding region), c.A153G (a silent mutation), and c.A709G (p.I237V). In CHO-K1, it is possible that one PAICS allele has isoleucine Fig. 2 . DNA sequence of PAICS-K1 cloned into pTarget. The adenine in the start (ATG) codon is designated +1. Mutations identified in AdeD are underlined: c.G1088A (p.W363*) and c.G529A (p.E177K). PAICS DNA sequence in capital letters represents the truncated cDNA sequence from JP049561.1. PAICS DNA sequence from the predicted sequence, NCBI XM_003513528.1, is in lowercase letters. Our K1 PAICS sequence is presented and differs from our XM_003513528.1: JP049561.1 reference sequence at c.G-5A and c.A153G (a silent mutation). The valine (V) at position p.237 (c.A709G) differs from the published K1 PAICS, JP049561.1, which when translated has isoleucine (I) at this position. at p.237 and the other has valine. The PAICS sequence in our pTarget clone has p.237V. Both JP049561.1 and XM_003513528.1 have c.A709 (p.I237), however valine is evolutionarily conserved at p.237 [28] . We hypothesized that the two PAICS variants in AdeD represent two different PAICS alleles. To test this, we ligated AdeD PAICS cDNA into pTarget and isolated subclones for sequencing. Some subclones contained the c.G529A (p.E177K) variant, and some contained the c.G1088A (p.W363*) variant. The c.A709G (p.I237V) variant was present only in c.G529A (p.E177K) subclones (Fig. 3A) . None of the PAICS-AdeD-pTarget clones had the wild type sequence. The PAICS cDNA sequence from K1, and from both AdeD alleles in our pTarget clones, have been deposited in GenBank (NCBI accession numbers KC176530, KC176531, and KC176532). The AdeD p.E177K allele (KC176531) is referred to as "allele 1" and the p.W363* allele (KC176532) is referred to as "allele 2".
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The mutations in AdeD lead to lack of detectable PAICS protein
The p.W363* PAICS variant would be expected to be incapable of producing a full-length protein. However, to address the possibility that the p.E177K variant produces a full-length inactive protein, we carried out Western blot analysis of protein extracts from CHO-K1 and AdeD. The result demonstrates that CHO-K1 contains PAICS protein as expected. However, AdeD does not contain detectable levels of PAICS protein (Fig. 4) . We also assessed whether PAICS is present in AdeI, which has a mutation in ADSL, the next enzyme in the de novo purine biosynthetic pathway. PAICS is abundant in AdeI cells. Two proteins of similar molecular weight were detected, possibly representing different PAICS isoforms.
AdeD produces abundant amounts of PAICS mRNA
We performed qPCR to determine the level of PAICS mRNA in AdeD and CHO-K1 cells. Fig. 5 shows the relative fold expression of PAICS mRNA in CHO-K1 and AdeD cells. There was no significant difference in PAICS transcript levels in AdeD cells compared to CHO-K1.
Alleviation of the purine requirement of AdeD cells by transfection with CHO-PAICS cDNA
To confirm that the AdeD mutations inactivate PAICS, we constructed vectors with wild type (WT) and both mutant PAICS cDNAs. We then transfected AdeD cells with each of the PAICS vectors. As expected, transfection with WT PAICS cDNA rescued the AdeD purine requirement, but transfection with either mutant clone did not. This demonstrates that the mutations in AdeD inactivate PAICS (Fig. 6) .
HPLC-EC analysis of AdeI and AdeD intermediate accumulation
We previously demonstrated that AdeD cells accumulate an intermediate presumed to be AIR [9] . To confirm that this intermediate is indeed AIR, we devised a simple method for detecting AIR that does not depend on radioisotopic labeling. Using HPLC-EC, we found that AdeD accumulates two compounds upon incubation in purine-free medium. To determine whether one of these is AIR, we performed HPLC-EC analyses employing standard AIR (validated by mass spectroscopic analysis, using a method devised in our laboratory to be described elsewhere) and demonstrated that AIR co-elutes, and co-oxidizes, with one of the two compounds. The purine deprived cells show accumulation of a major peak with a retention time of 5 min when compared with adenine supplemented cells (Figs. 7A, B) . The addition of AIR to the AdeD sample from cells incubated in purine-free media does not yield a new peak, but instead increases the intensity of an existing peak. AIR standard alone yields a significant peak with the same 5 min retention time and the same oxidation pattern.
Similarly, we examined the accumulation of purine intermediates in AdeI cells. When cultured in purine-free media, AdeI cells accumulate a compound identified as SAICAR (Figs. 8B, C) . They also accumulate 
K1 AdeD
Normalized Fold Expression Fig. 5 . qPCR analysis of PAICS mRNA levels in CHO-K1 and AdeD cells. Total RNA was isolated and cDNA was prepared from each cell line. Normalized fold expression levels of PAICS transcript in K1 and AdeD was quantified by qPCR, in triplicate, using CHO PAICS specific primers and beta-actin reference gene primers. Relative expression levels were determined using the ΔΔCt method. an additional compound that appears from retention time and oxidation characteristics to be the same compound accumulated by purinedepleted AdeD. Co-chromatography of AdeI extracts with standard AIR confirms that AdeI, like AdeD, accumulates AIR (Fig. 8D ). There are no differences detected in the intermediate accumulation of starved versus unstarved CHO-K1 cells.
Discussion
Analysis of AdeD PAICS cDNA sequences revealed two sequence variants, p.E177K and p.W363* which map to separate alleles. AdeD was produced by treatment of CHO cells with EMS, which induces point mutations, consistent with our characterized (point) mutants. The CHO-K1 variants c.G-5A and c.A153G probably have no consequence for PAICS protein structure and function. One is upstream of the start codon and the other is silent. The c.G-5A and c.A153G variants differ from the predicted CHO PAICS sequence (NCBI XM_003513528.1, 2168 bp).
Except for p.W363* (AdeD), p.E177K (AdeD), and p.I237V [AdeD (the p.I237V allele) and CHO-K1], no other differences were found comparing our AdeD and CHO-K1 PAICS sequences to JP049561.1. These three variants were identified both by RT-PCR and by sequencing the inserts of pTarget clones containing the PAICS cDNA from either CHO-K1 or AdeD cells. Transfection of AdeD cells with WT and mutant PAICS vectors demonstrates that WT PAICS cDNA rescues the AdeD purine requirement, but transfection with either mutant cDNA does not. Western blot analysis demonstrated expression of PAICS protein in CHO-K1 and in AdeI, but not in AdeD. These results and the observed abundance of PAICS mRNA in AdeD cells strongly suggest that both the mutations observed in PAICS lead to the production of truncated and/or unstable protein.
The p.E177K substitution is located in the SAICARs domain of PAICS in an alpha helical (α4) region of the protein important for the interaction of the SAICARs and AIRc domains as well as the maintenance of SAICARs' structure (Fig. 3) . It may also play a role in substrate channeling within PAICS [28] . The fly, frog, chicken, cattle, mouse, and human PAICS all have p.E177 in the α4 helix [28] . At physiological pH, glutamate (E) is negatively charged. In the structure for human PAICS (2H31.pdb) [28] , p.E177 is extremely close to p.R102 (arginine), which is located next to β6, between β6 and α2. Arginine is positively charged, and it is possible that attraction between p.E177 and p.R102 in the wild type protein may play a role in stabilizing the PAICS monomer structure. If this is the case, p.K177 (lysine) would be disruptive; it is positively charged, so rather than attraction between it and p.R102, it would most likely repel p.R102. In addition, K has a longer side chain than E, so steric hindrance may also be a destabilizing factor. This is consistent with the possibility that the mutation affects the folding of AdeD PAICS, thus leading to an unstable protein. Indeed, analysis of this mutation using PoPMuSiC 2.1 calculates a ΔΔG of 0.41 and predicts that this is a destabilizing mutation for PAICS [29, 30] .
It is unlikely that the p.W363* mutant monomer could participate in the octameric form of the PAICS protein since structures beyond the carboxyl end of p.362, such as the α10 and α11 helices believed to form the dyad symmetry interface crucial for the assembly of the octamer, and loop 4, which form part of the AIRc active site [28] , would be absent. The seven-turn α11 helix interacts with the six-turn α4 helix in a coiled coil, so this interaction would be absent as well (Fig. 3) . AIRc activity and assembly of an octamer would be highly unlikely [28] .
Previously, we characterized mutations in AdeI (A291V in ADSL) and AdeC and AdeG (both deficient in trifunctional GART activity) [10, 31] . Here we report the characterization of two sequence variants, p.E177K and p.W363*, in two PAICS alleles that are responsible for the purine auxotrophy observed in AdeD. Thus, defined mutants exist in 3 of the 6 proteins required for de novo purine biosynthesis in mammalian cells. We are currently characterizing the mutations in the other mutant CHO cell lines (Fig. 1) .
We have reported previously that isolates of AdeC and AdeG produce markedly reduced or undetectable levels of trifunctional GART (triGART) protein and also of monofunctional GARS [32] . In addition we have published evidence that CHO-K1 AdeB mutants produce undetectable levels of FGAMS (phosphoribosylformylglycinamidine) [33, 34] . We have also reported a mutant CHO-K1 cell that overproduces FGAMS [33] . Deng et al. [2] recently presented evidence supporting the hypothesis that triGART and FGAMS are core components of the purinosome and that PPAT and FGAMS interact intracellularly, a hypothesis we proposed previously on the basis of somatic cell genetic evidence [35] . These mutations, resulting in altered levels of de novo One difficulty in the analysis of de novo purine biosynthesis is that robust methods that are not reliant on the use of radioisotopes to detect and quantify pathway intermediates from small samples of cells are not readily available. Our analysis of AdeD and AdeI demonstrates the utility of HPLC-EC for these studies. The method has provided convincing evidence that AdeD cells incubated in purine-free conditions accumulate AIR, the initial substrate of the bifunctional enzyme PAICS (Figs. 7B, C) . Similarly, HPLC-EC readily detects accumulation of SAICAR in AdeI cells (Figs. 8B, C) .
HPLC-EC has provided new insights into intermediate accumulation under conditions of purine depletion. For example, AdeI cells incubated in purine-free media accumulate AIR in addition to SAICAR. AdeI cells have virtually undetectable levels of ADSL activity. It is not clear whether cells from ADSL deficiency patients accumulate AIR or not, since cells tested to date all have significant residual ADSL activity [36] [37] [38] [39] . If AIR does accumulate in these cells, it may potentially play a role in pathogenetic mechanisms of ADSL deficiency.
HPLC-EC analysis demonstrates that AdeD and AdeI cells accumulate a second compound that was not identified. The de novo pathway suggests that this compound may be carboxy-AIR (CAIR), the substrate of the second sequential step catalyzed by PAICS. However, the lack of detectable PAICS protein argues against this interpretation. Other possibilities are that the compound may be aminoimidazole riboside, or aminoimidazole, or an earlier intermediate in the pathway. HPLC-EC offers many advantages for these analyses. Samples undergo redox reactions with 100% efficiency, and the series of incremental voltages allows for high specificity and resolution of co-eluting compounds. HPLC-EC is also extremely sensitive, capable of detecting 1-10 pg of a given compound. Detection of SAICAR is about 200 times more sensitive by EC than by UV. Detection of AIR by UV is possible, but absorption is relatively low. The molar extinction coefficient for AIR (250 nm, pH 6) is 4170 M −1 cm −1 [40] . Our results demonstrate the utility of HPLC-EC as a detection method for investigating the de novo purine biosynthesis pathway and detecting its intermediates. We are currently investigating the detection of other de novo purine biosynthesis intermediates using HPLC-EC. Current clinical methods used to test for purine intermediate accumulation generally detect dephosphorylated compounds in bodily fluids. HPLC-EC is sufficiently sensitive that it can likely be used to detect the true pathway intermediates in clinically relevant samples such as skin biopsies, fibroblast cultures, or small blood samples. Additionally, HPLC-EC methods could be devised to detect dephosphorylated compounds.
